Novavax Short
Pfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness to the game will not serve them well here . The biggest dangers to NVAX are now the regulatory agencies taking long/asking for additional info and the COVID-19 Antiviral drug news ( Merck's pill approval will be this months and Pfizer may come out with their Phase III study result any moment now). Both are very likely .
NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .
NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.